Lee, Dohyun Lee, Woo-Sirl Lim, Sungsu Kim, Yun Kyung Jung, Hoe-Yune Das, Sanket Lee, Juhyun Luo, Wenjie Kim, Kyong-Tai Chung, Sung-Kee 2024-01-20T00:32:13Z 2024-01-20T00:32:13Z 2021-09-03 2017-10 2045-2322 https://pubs.kist.re.kr/handle/201004/122257 Alzheimer's disease (AD) is a degenerative brain disease that destroys memory and other important mental functions but lacks efficient therapeutic agents. Blocking toxic amyloid beta (A beta) could be beneficial for AD and represents a promising therapeutic strategy for AD treatment. scyllo-Inositol (SI) is a potential therapeutic for AD by directly interacting with the A beta peptide to inhibit A beta 42 fiber formation. Clinical studies of SI showed promising benefits on mild to moderate AD, however, with limitations on dosage regime. A new strategy to enhance the brain delivery of SI is needed to achieve the efficacy with minimum adverse effects. Herein, we report that a novel guanidine-appended SI derivative AAD-66 resulted in more effective reductions of brain A beta and plaque deposits, gliosis, and behavioral memory deficits in the disease-established 5xFAD mice. Overall, our present study reveals the potential of AAD-66 as a promising therapeutic agent for AD. English Nature Publishing Group A guanidine-appended scyllo-inositol derivative AAD-66 enhances brain delivery and ameliorates Alzheimer's phenotypes Article 10.1038/s41598-017-14559-7 1 Scientific Reports, v.7 Scientific Reports 7 Y scie scopus 000413816000055 2-s2.0-85032486026 Multidisciplinary Sciences Science & Technology - Other Topics Article CONTAINING MOLECULAR TRANSPORTERS DISEASE MYOINOSITOL RECEPTOR DESIGN MICE